Your browser doesn't support javascript.
loading
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues, Anna; Arenas, Enrique J; Martínez-Sabadell, Alex; Brasó-Maristany, Fara; Cervera, Raimundo; Tormo, Eduardo; Hernando, Cristina; Martínez, María Teresa; Carbonell-Asins, Juan; Simón, Soraya; Poveda, Jesús; Moragón, Santiago; Zazo, Sandra; Martínez, Débora; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell, Joan; Bermejo, Begoña; Lluch, Ana; Prat, Aleix; Arribas, Joaquín; Eroles, Pilar; Cejalvo, Juan Miguel.
Afiliação
  • Adam-Artigues A; INCLIVA Biomedical Research Institute, Valencia 46010, Spain.
  • Arenas EJ; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain.
  • Martínez-Sabadell A; Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain.
  • Brasó-Maristany F; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain.
  • Cervera R; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona 08036, Spain.
  • Tormo E; Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona 08036, Spain.
  • Hernando C; INCLIVA Biomedical Research Institute, Valencia 46010, Spain.
  • Martínez MT; INCLIVA Biomedical Research Institute, Valencia 46010, Spain.
  • Carbonell-Asins J; Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain.
  • Simón S; INCLIVA Biomedical Research Institute, Valencia 46010, Spain.
  • Poveda J; Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain.
  • Moragón S; INCLIVA Biomedical Research Institute, Valencia 46010, Spain.
  • Zazo S; Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain.
  • Martínez D; INCLIVA Biomedical Research Institute, Valencia 46010, Spain.
  • Rovira A; Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain.
  • Burgués O; Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain.
  • Rojo F; Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain.
  • Albanell J; Department of Pathology, IIS Fundación Jiménez Díaz, Madrid 28040, Spain.
  • Bermejo B; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona 08036, Spain.
  • Lluch A; Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona 08036, Spain.
  • Prat A; Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain.
  • Arribas J; Department of Medical Oncology, Hospital del Mar, Barcelona 08003, Spain.
  • Eroles P; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona 08003, Spain.
  • Cejalvo JM; INCLIVA Biomedical Research Institute, Valencia 46010, Spain.
Sci Adv ; 8(20): eabk2746, 2022 05 20.
Article em En | MEDLINE | ID: mdl-35594351
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Sci Adv Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Sci Adv Ano de publicação: 2022 Tipo de documento: Article